Comparable Outcomes of Ultrasound versus Computed Tomography in the Guidance of Radiofrequency Ablation for Hepatocellular Carcinoma

Lu-Hung Lee, Jen-I Hwang, Yu-Chi Cheng, Chun-Ying Wu, Shou-Wu Lee, Sheng-Shun Yang, Hong-Zen Yeh, Chi-Sen Chang, Teng-Yu Lee, Lu-Hung Lee, Jen-I Hwang, Yu-Chi Cheng, Chun-Ying Wu, Shou-Wu Lee, Sheng-Shun Yang, Hong-Zen Yeh, Chi-Sen Chang, Teng-Yu Lee

Abstract

Objectives: To compare the efficacy and safety of ultrasound (US) and computed tomography (CT) in the guidance of radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC).

Materials and methods: We retrospectively analyzed consecutive treatment-naïve patients who received curative RFA for HCC from January 2008 to July 2013. Patients were divided into the US group or the CT group according to their RFA guidance instruments. Patients who were only suitable for US- or CT-guided RFA were excluded. Cumulative incidences of and hazard ratios for HCC recurrence were analyzed after adjusting for competing mortality risk.

Results: We recruited a total of 101 patients in the US group and 51 patients in the CT group. The baseline demographic characteristics were not significantly different in both groups. Initial response rates were similar between the two groups (US vs. CT: 89.1% vs. 92.2%, p = 0.54), and complete tumor ablation was finally achieved for all patients. However, more ablations per session were performed in US group (median 2.0 [1.0-3.0] vs. 1.0 [1.0-2.0]; p<0.01). The 1-, 2- and 3-year local tumor recurrence rates (US vs. CT: 13.0%, 20.9%, and 29.2% vs. 11.2%, 29.8% and 29.8%, respectively) and overall mortality rates (US vs. CT: 5.2%, 9.6% and 16.5% vs. 0%, 3.1% and 23.8%, respectively) were not significantly different. In multivariate analysis, tumor characteristics and underlying liver function, but not US or CT guidance, were independent prognostic factors. The complication rates were similar between the two groups (US vs. CT: 10.9% vs. 9.8%; p = 0.71), and there was no procedure-related mortality.

Conclusions: With comparable major outcomes, either US or CT can be used in the guidance of RFA in experience hands.

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1. Local tumor progression and overall…
Fig 1. Local tumor progression and overall tumor recurrence in the US group and the CT group.
(A) Cumulative incidences of local tumor progression. (B) Cumulative incidences of overall tumor recurrence.
Fig 2. Liver-related mortality and overall mortality…
Fig 2. Liver-related mortality and overall mortality in the US group and the CT group.
(A) Cumulative incidences of liver-related mortality rates. (B) Cumulative incidences of overall mortality.

References

    1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. 10.3322/caac.21262
    1. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol. 2008;48 Suppl 1:S20–37.
    1. Chan AC, Poon RT, Ng KK, Lo CM, Fan ST, Wong J. Changing paradigm in the management of hepatocellular carcinoma improves the survival benefit of early detection by screening. Ann Surg. 2008;247(4):666–73. 10.1097/SLA.0b013e31816a747a
    1. European Association For The Study Of The L, European Organisation For R, Treatment Of C. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908–43. 10.1016/j.jhep.2011.12.001
    1. Bruix J, Sherman M, American Association for the Study of Liver D. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020–2. 10.1002/hep.24199
    1. Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int. 2010;4(2):439–74. 10.1007/s12072-010-9165-7
    1. Feng K, Yan J, Li X, Xia F, Ma K, Wang S, et al. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. J Hepatol. 2012;57(4):794–802. 10.1016/j.jhep.2012.05.007
    1. Chen MS, Li JQ, Zheng Y, Guo RP, Liang HH, Zhang YQ, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg. 2006;243(3):321–8. 10.1097/01.sla.0000201480.65519.b8
    1. Laspas F, Sotiropoulou E, Mylona S, Manataki A, Tsagouli P, Tsangaridou I, et al. Computed tomography-guided radiofrequency ablation of hepatocellular carcinoma: treatment efficacy and complications. J Gastrointestin Liver Dis. 2009;18(3):323–8.
    1. Lencioni R, Cioni D, Crocetti L, Franchini C, Pina CD, Lera J, et al. Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. Radiology. 2005;234(3):961–7. 10.1148/radiol.2343040350
    1. Shiina S, Tateishi R, Arano T, Uchino K, Enooku K, Nakagawa H, et al. Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol. 2012;107(4):569–77; quiz 78. 10.1038/ajg.2011.425
    1. Park BJ, Byun JH, Jin YH, Won HJ, Shin YM, Kim KW, et al. CT-guided radiofrequency ablation for hepatocellular carcinomas that were undetectable at US: therapeutic effectiveness and safety. J Vasc Interv Radiol. 2009;20(4):490–9. 10.1016/j.jvir.2009.01.004
    1. Kim JE, Kim YS, Rhim H, Lim HK, Lee MW, Choi D, et al. Outcomes of patients with hepatocellular carcinoma referred for percutaneous radiofrequency ablation at a tertiary center: analysis focused on the feasibility with the use of ultrasonography guidance. Eur J Radiol. 2011;79(2):e80–4. 10.1016/j.ejrad.2011.03.090
    1. Cha CH, Lee FT Jr., Gurney JM, Markhardt BK, Warner TF, Kelcz F, et al. CT versus sonography for monitoring radiofrequency ablation in a porcine liver. AJR Am J Roentgenol. 2000;175(3):705–11. 10.2214/ajr.175.3.1750705
    1. Sheafor DH, Paulson EK, Simmons CM, DeLong DM, Nelson RC. Abdominal percutaneous interventional procedures: comparison of CT and US guidance. Radiology. 1998;207(3):705–10. 10.1148/radiology.207.3.9609893
    1. Kliewer MA, Sheafor DH, Paulson EK, Helsper RS, Hertzberg BS, Nelson RC. Percutaneous liver biopsy: a cost-benefit analysis comparing sonographic and CT guidance. AJR Am J Roentgenol. 1999;173(5):1199–202. 10.2214/ajr.173.5.10541088
    1. Sheafor DH, Paulson EK, Kliewer MA, DeLong DM, Nelson RC. Comparison of sonographic and CT guidance techniques: does CT fluoroscopy decrease procedure time? AJR Am J Roentgenol. 2000;174(4):939–42. 10.2214/ajr.174.4.1740939
    1. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or = 4 cm. Gastroenterology. 2004;127(6):1714–23.
    1. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut. 2005;54(8):1151–6. 10.1136/gut.2004.045203
    1. N'Kontchou G, Mahamoudi A, Aout M, Ganne-Carrie N, Grando V, Coderc E, et al. Radiofrequency ablation of hepatocellular carcinoma: long-term results and prognostic factors in 235 Western patients with cirrhosis. Hepatology. 2009;50(5):1475–83. 10.1002/hep.23181
    1. Lee TY, Lin JT, Ho HJ, Wu MS, Wu CY. Evaluation of the Effect of Cumulative Operator Experience on Hepatocellular Carcinoma Recurrence after Primary Treatment with Radiofrequency Ablation. Radiology. 2015;276(1):294–301. 10.1148/radiol.15141864
    1. Ahmed M, Solbiati L, Brace CL, Breen DJ, Callstrom MR, Charboneau JW, et al. Image-guided tumor ablation: standardization of terminology and reporting criteria—a 10-year update. Radiology. 2014;273(1):241–60. 10.1148/radiol.14132958
    1. Teratani T, Yoshida H, Shiina S, Obi S, Sato S, Tateishi R, et al. Radiofrequency ablation for hepatocellular carcinoma in so-called high-risk locations. Hepatology. 2006;43(5):1101–8. 10.1002/hep.21164
    1. Huang J, Yan L, Cheng Z, Wu H, Du L, Wang J, et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg. 2010;252(6):903–12. 10.1097/SLA.0b013e3181efc656
    1. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988;16:1141–115425.
    1. Wu J, Chen P, Xie YG, Gong NM, Sun LL, Sun CF.Comparison of the effectiveness and safety of ultrasound- and CT-guided percuaneous radiogrequency ablation of non-operation hepatocellular carcinoma.2015;21(3):637–42.
    1. Crocetti L, Lencioni R, Debeni S, See TC, Pina CD, Bartolozzi C. Targeting liver lesions for radiofrequency ablation: an experimental feasibility study using a CT-US fusion imaging system. Invest Radiol. 2008;43(1):33–9. 10.1097/RLI.0b013e31815597dc
    1. Kang TW, Lim HK, Lee MW, Kim YS, Choi D, Rhim H. First-line radiofrequency ablation with or without artificial ascites for hepatocellular carcinomas in a subcapsular location: local control rate and risk of peritoneal seeding at long-term follow-up. Clin Radiol. 2013;68(12):e641–51. 10.1016/j.crad.2013.07.008
    1. Kondo Y, Yoshida H, Tateishi R, Shiina S, Kawabe T, Omata M. Percutaneous radiofrequency ablation of liver cancer in the hepatic dome using the intrapleural fluid infusion technique. Br J Surg. 2008;95(8):996–1004. 10.1002/bjs.6058
    1. Uehara T, Hirooka M, Ishida K, Hiraoka A, Kumagi T, Kisaka Y, et al. Percutaneous ultrasound-guided radiofrequency ablation of hepatocellular carcinoma with artificially induced pleural effusion and ascites. J Gastroenterol. 2007;42(4):306–11. 10.1007/s00535-006-1949-0
    1. Lee MW, Lim HK, Kim YJ, Choi D, Kim YS, Lee WJ, et al. Percutaneous sonographically guided radio frequency ablation of hepatocellular carcinoma: causes of mistargeting and factors affecting the feasibility of a second ablation session. J Ultrasound Med. 2011;30(5):607–15.
    1. Kim YJ, Lee MW, Park HS. Small hepatocellular carcinomas: ultrasonography guided percutaneous radiofrequency ablation. Abdom Imaging. 2013;38(1):98–111. 10.1007/s00261-012-9883-5
    1. Clasen S, Rempp H, Hoffmann R, Graf H, Pereira PL, Claussen CD. Image-guided radiofrequency ablation of hepatocellular carcinoma (HCC): is MR guidance more effective than CT guidance? Eur J Radiol. 2014;83(1):111–6. 10.1016/j.ejrad.2013.09.018
    1. Park Y, Choi D, Rhim H, Kim YS, Lee JY, Chang I, et al. Central lower attenuating lesion in the ablation zone on immediate follow-up CT after percutaneous radiofrequency ablation for hepatocellular carcinoma: incidence and clinical significance. Eur J Radiol. 2010;75(3):391–6. 10.1016/j.ejrad.2009.04.054
    1. Clasen S, Rempp H, Boss A, Schmidt D, Fritz J, Schraml C, et al. MR-guided radiofrequency ablation of hepatocellular carcinoma: long-term effectiveness. J Vasc Interv Radiol. 2011;22(6):762–70. 10.1016/j.jvir.2011.03.006
    1. Chen MH, Wu W, Yang W, Dai Y, Gao W, Yin SS, et al. The use of contrast-enhanced ultrasonography in the selection of patients with hepatocellular carcinoma for radio frequency ablation therapy. J Ultrasound Med. 2007;26(8):1055–63.
    1. Maruyama H, Takahashi M, Ishibashi H, Okugawa H, Okabe S, Yoshikawa M, et al. Ultrasound-guided treatments under low acoustic power contrast harmonic imaging for hepatocellular carcinomas undetected by B-mode ultrasonography. Liver Int. 2009;29(5):708–14. 10.1111/j.1478-3231.2008.01875.x
    1. Kitada T, Murakami T, Kuzushita N, Minamitani K, Nakajo K, Osuga K, et al. Effectiveness of real-time virtual sonography-guided radiofrequency ablation treatment for patients with hepatocellular carcinomas. Hepatol Res. 2008;38(6):565–71. 10.1111/j.1872-034X.2007.00308.x

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel